New advances in the management of juvenile idiopathic arthritis--1: non-biological therapy

Area of Science:

• Pediatric Rheumatology
• Immunology
• Clinical Medicine

Background:

• Juvenile idiopathic arthritis (JIA) is a leading pediatric rheumatic condition with substantial long-term health impacts.
• Recent years have seen significant progress in understanding and managing JIA, driven by collaborative efforts.
• Specialized expertise and improved outcome measures are crucial for effective JIA patient management.

Purpose of the Study:

• To review recent advancements in non-biological therapies for juvenile idiopathic arthritis.
• To highlight key developments in JIA treatment strategies.
• To provide an overview of current evidence-based approaches for JIA management.

Main Methods:

• Literature review of recent clinical trials and evidence-based guidelines.
• Analysis of advancements in non-biological treatment modalities for JIA.
• Synthesis of data on optimized therapeutic strategies and emerging treatments.

Main Results:

• Early intra-articular corticosteroid injections demonstrate long-lasting effects, alone or with systemic treatments.
• Methotrexate is established as a first-line disease-modifying anti-rheumatic drug for JIA.
• Novel treatments, including stem cell transplantation, are available for severe, refractory JIA cases.

Conclusions:

• Optimized non-biological therapies represent significant progress in JIA management.
• Multidisciplinary collaboration and evidence-based treatments are vital for improving JIA outcomes.
• Continued research into JIA therapies promises further improvements in patient care and prognosis.